Plate Nº 54 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Nanoparticle mRNA Therapy Shrinks Lung Tumors 2.5-Fold in Mice
Oregon State University researchers built lipid nanoparticles that carry follistatin mRNA to lung tumors, cutting tumor burden in mice about 2.5-fold versus standard particles.
By Priya Raman3 min read586 words
In brief
- The nanoparticle therapy achieved roughly a 2.5-fold greater reduction in tumor burden than conventional LNPs in mice.
- The study, led by Oleh Taratula and Yoon Tae Goo, appeared in the Journal of Controlled Release on October 5, 2026.
- Cachexia, the muscle-wasting condition the therapy also targets, can kill up to 30% of cancer patients it affects.
- The American Cancer Society projects about 230,000 new U.S. lung cancer cases and 125,000 deaths this year.
- The work is preclinical; no human testing has occurred yet.
An experimental nanoparticle therapy cut lung tumor burden in mice roughly 2.5 times more effectively than conventional particles, according to researchers at Oregon State University. The same treatment also tackles cachexia, the severe muscle-wasting condition that affects many cancer patients.
The team, led by Oleh Taratula and Yoon Tae Goo of the OSU College of Pharmacy, published its results in the Journal of Controlled Release on October 5, 2026. The work remains preclinical, meaning no human has yet received the therapy.
How does the treatment work?
The researchers used lipid nanoparticles, or LNPs — tiny fatty particles measuring between one and 100 billionths of a meter — to carry messenger RNA into the body intravenously. Messenger RNA, or mRNA, is genetic instructions that tell cells which proteins to build.
In this case, the mRNA directs cells to produce follistatin, a protein that can both suppress tumor growth and support muscle tissue growth.
The key innovation lies in how the particles find their target. "We found that these LNPs bind vitronectin in the bloodstream, which then directs them to lung cancer tumors by interacting with integrin receptors that are overexpressed on the tumor surface," Taratula said.
Vitronectin is a protein naturally present in blood serum. Integrin receptors sit on the cell surface and help cells sense and respond to their surroundings. Lung tumors carry unusually large numbers of these receptors, which effectively pulls the particle-bound vitronectin toward the cancer.
Why has lung delivery been so hard?
Getting mRNA therapies to lung tumors through the bloodstream has stumped researchers for years. Conventional lipid nanoparticles tend to accumulate in the liver instead of reaching cancer cells, limiting their usefulness against lung disease.
"Systemic delivery of mRNA therapeutics to lung cancer tumors has been a significant challenge in our field, and this work offers a promising solution," Taratula said.
The stakes are high. Lung cancer is the third most common cancer in the United States and the leading cause of cancer death. The American Cancer Society estimates about 230,000 new U.S. diagnoses this year, with roughly 125,000 deaths. Overall, about 5% of people will develop lung cancer at some point, and smokers face elevated risk.
What is cachexia, and why target it too?
Cachexia is a devastating complication of cancer. It causes severe weight and muscle loss and can kill as many as 30% of the cancer patients it affects.
Unlike ordinary weight loss, cachexia does not stop when a patient eats enough food. Patients lose both body fat and significant amounts of muscle.
The OSU team chose follistatin deliberately: one protein, two jobs.
"By loading our LNPs with follistatin mRNA, we developed a therapy that simultaneously targets lung cancer and cancer cachexia, all without adverse effects," Taratula said.
When could this reach patients?
Not soon, and the researchers say so plainly. "More preclinical work is necessary, but we're very encouraged by what we've seen so far and hope that testing in humans is down the road," Taratula said.
The mouse results, while promising, do not guarantee similar outcomes in people. Additional studies must establish safety and effectiveness before human trials can begin.
Co-authors included Vladislav Grigoriev, Tetiana Korzun, Ammar Salem, Kongbrailatpam Shitaljit Sharma, Prem Singh, Chrissa Kioussi and Olena Taratula of the College of Pharmacy, plus Daniel Marks of Endevica Bio, a company developing peptide therapies. The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea funded the work.
via news.oregonstate.edu (Original)
More from Priya Raman
Show full bio
Senior reporter covering industry trends and analytics at SciBeat.
207 articles
Nearby plates
- MIT Automates Lipid Nanoparticle Production for RNA Therapies
- New Drug CS18 Reverses Cancer Treatment Resistance in Lab Tests
- mRNA Cancer Vaccine Plus Keytruda Boosts Melanoma Survival
- Single Molecule Reverses Prostate Cancer Drug Resistance in Lab
- AI-Designed RNA Vaccines Stay Stable for a Year at Room Temperature